Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : BLUE save search
bluebird bio, Inc. Announces Pricing of $120 Million Public Offering of Common Stock
Published: 2023-01-19 (Crawled : 08:00) - biospace.com/
BLUE | $0.9229 -4.91% -4.66% 7.9M
|
Health Technology
|
| O: 1.91%
H: 0.81%
C: -3.58%
offering
bluebird bio, Inc. Announces Proposed Public Offering of Common Stock
Published: 2023-01-18 (Crawled : 13:00) - biospace.com/
BLUE | $0.9229 -4.91% -4.66% 7.9M
|
Health Technology
|
| O: -9.07%
H: 4.98%
C: -8.99%
offering
bluebird bio Provides Update on Commercial Launch Progress, Program Milestones and 2023 Financial Outlook Ahead of Company Presentation at 41st Annual J.P. Morgan Healthcare Conference
Published: 2023-01-09 (Crawled : 12:20) - biospace.com/
BLUE | $0.9229 -4.91% -4.66% 7.9M
|
Health Technology
|
| O: 1.15%
H: 0.44%
C: -5.16%
conference commercial program presentation financial update
bluebird bio Sells Second Priority Review Voucher for $95 Million
Published: 2023-01-06 (Crawled : 17:00) - biospace.com/
BLUE | $0.9229 -4.91% -4.66% 7.9M
|
Health Technology
|
| O: 0.76%
H: 1.28%
C: -1.01%
review
bluebird bio to Present at the 41st Annual J.P. Morgan Healthcare Conference
Published: 2023-01-05 (Crawled : 14:20) - biospace.com/
BLUE | $0.9229 -4.91% -4.66% 7.9M
|
Health Technology
|
| O: -0.53%
H: 7.53%
C: 4.1%
conference
bluebird bio Appoints Joseph Vittiglio, JD, as Chief Business and Legal Officer
Published: 2023-01-03 (Crawled : 14:00) - biospace.com/
BLUE | $0.9229 -4.91% -4.66% 7.9M
|
Health Technology
|
| O: 2.02%
H: 3.19%
C: -1.7%
FDA Lifts Partial Clinical Hold for bluebird bio’s Sickle Cell Disease (SCD) Studies for Patients Under the Age of 18
Published: 2022-12-19 (Crawled : 13:00) - biospace.com/
BLUE | $0.9229 -4.91% -4.66% 7.9M
|
Health Technology
|
| O: 0.0%
H: 1.23%
C: -6.75%
fda disease clinical hold
bluebird bio Sells Priority Review Voucher for $102 Million
Published: 2022-11-30 (Crawled : 18:00) - biospace.com/
BLUE | $0.9229 -4.91% -4.66% 7.9M
|
Health Technology
|
| O: 0.65%
H: 3.7%
C: 1.17%
review
bluebird bio Reports Third Quarter 2022 Financial Results and Highlights Operational Progress
Published: 2022-11-07 (Crawled : 13:20) - biospace.com/
BLUE | $0.9229 -4.91% -4.66% 7.9M
|
Health Technology
|
| O: 1.14%
H: 11.61%
C: 9.84%
financial results
bluebird bio Announced September Investor Events
Published: 2022-08-29 (Crawled : 13:00) - biospace.com/
MS | News 0 d | $93.85 0.1% -0.02% 3.3M
|
Finance
|
| O: -0.77%
H: 0.34%
C: -0.92%
BLUE | $0.9229 -4.91% -4.66% 7.9M
|
Health Technology
|
| O: -1.35%
H: 5.81%
C: 0.85%
bluebird bio Announces U.S. Commercial Infrastructure to Enable Patient Access to ZYNTEGLO®, the First and Only FDA-Approved Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions
Published: 2022-08-17 (Crawled : 22:00) - biospace.com/
BLUE | $0.9229 -4.91% -4.66% 7.9M
|
Health Technology
|
| O: -4.41%
H: 30.05%
C: 7.79%
zynteglo blood commercial therapy
bluebird bio Announces FDA Approval of ZYNTEGLO®, the First Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions
Published: 2022-08-17 (Crawled : 22:00) - biospace.com/
BLUE | $0.9229 -4.91% -4.66% 7.9M
|
Health Technology
|
| O: -4.41%
H: 30.05%
C: 7.79%
zynteglo fda blood approval therapy
FDA Approves First Cell-Based Gene Therapy to Treat Adult and Pediatric Patients with Beta-thalassemia Who Require Regular Blood Transfusions
Published: 2022-08-17 (Crawled : 18:00) - prnewswire.com
BLUE | $0.9229 -4.91% -4.66% 7.9M
|
Health Technology
|
| O: -4.41%
H: 30.05%
C: 7.79%
fda blood therapy
Global Genome Engineering Market to Surpass US$ 15,195.74 Million by 2030 - Coherent Market Insights
Published: 2022-07-15 (Crawled : 18:00) - prnewswire.com
TMO | News | $577.39 0.49% 0.0% 2M
|
Health Technology
|
| O: 1.5%
H: 1.27%
C: 1.0%
SGMO | News | $0.493 -5.36% -6.07% 1.2M
|
Health Technology
|
| O: 1.98%
H: 0.0%
C: -1.94%
NTLA | $21.17 -1.67% -1.75% 710K
|
Health Technology
|
| O: 0.36%
H: 0.0%
C: -1.13%
GILD | $67.08 0.08% 0.06% 6.2M
|
Health Technology
|
| O: 0.52%
H: 0.79%
C: 0.76%
EDIT | News | $5.35 -2.02% -1.96% 1.2M
|
Health Technology
|
| O: 2.46%
H: 0.0%
C: -2.91%
CRSP | News 4 | $55.65 -1.35% -1.35% 790K
|
Health Technology
|
| O: 0.0%
H: 1.81%
C: 1.81%
CLLS | News | $2.5 -4.57% -3.55% 39K
|
Health Technology
|
| O: -2.43%
H: 3.32%
C: 2.07%
BLUE | $0.9229 -4.91% -4.66% 7.9M
|
Health Technology
|
| O: 0.2%
H: 1.41%
C: -2.83%
global market
Global Gene Therapy Market Research Report 2022-2031 Featuring Major Players - Novartis AG; Bluebird bio, Inc.; Spark Therapeutics, Inc; Audentes Therapeutics; Voyager Therapeutics
Published: 2022-06-20 (Crawled : 12:00) - prnewswire.com
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $94.0 -0.27% -2.18% 310
|
Health Technology
| Email alert
Add to watchlist
QURE | $4.56 -4.0% -3.94% 640K
|
Health Technology
| Email alert
Add to watchlist
CLLS | News | $2.5 -4.57% -3.55% 39K
|
Health Technology
| Email alert
Add to watchlist
SRPT | $124.27 6.11% 5.75% 1.3M
|
Health Technology
| Email alert
Add to watchlist
NVSEF | News | $96.0 0.94% 6.88% 0
|
Health Technology
| Email alert
Add to watchlist
AGTC | News | $0.3936 1.23% 0.0%
|
Health Technology
| Email alert
Add to watchlist
BLUE | $0.9229 -4.91% -4.66% 7.9M
|
Health Technology
| Email alert
Add to watchlist
NVS | News | $98.35 1.1% 0.69% 2.1M
|
Health Technology
| Email alert
Add to watchlist
research report novartis therapeutics therapy market
Xilio Therapeutics Announces Promotion of Martin Huber, M.D., to President
Published: 2022-06-16 (Crawled : 14:20) - biospace.com/
XLO | $1.06 0.95% 0.94% 300K
|
Professional, Scientific, and T...
|
| O: 1.32%
H: 1.73%
C: -3.9%
GLAXF | News | $19.54 -3.77% -14.18% 170
|
Health Technology
|
| O: -0.07%
H: 2.34%
C: 0.33%
GSK | News | $40.86 -0.92% 1.25% 1.6M
|
Health Technology
|
| O: -1.1%
H: 0.0%
C: 0.0%
SNDX | $20.79 -0.86% -0.87% 370K
|
Health Technology
|
| O: -2.65%
H: 0.76%
C: 0.06%
SURF | $1.07 -0.93% -1.41% 0
|
Health Technology
|
| O: -1.96%
H: 0.67%
C: -5.33%
MRSN | $2.88 -10.28% -11.07% 3.5M
|
Health Technology
|
| O: -3.79%
H: 3.28%
C: 3.28%
INFI | $0.016 12.5% 1.1M
|
Health Technology
|
| O: -1.32%
H: 0.01%
C: -5.65%
INCY | $51.74 0.17% 0.14% 1.6M
|
Health Technology
|
| O: -2.17%
H: 1.76%
C: 1.46%
EXAS | $63.24 -0.46% -0.46% 980K
|
Health Technology
|
| O: -4.37%
H: 0.14%
C: -3.76%
BLUE | $0.9229 -4.91% -4.66% 7.9M
|
Health Technology
|
| O: -4.31%
H: 0.9%
C: -8.11%
BIIB | $201.99 4.56% 4.32% 2.7M
|
Health Technology
|
| O: -2.0%
H: 0.29%
C: -0.93%
AGIO | $31.67 -0.44% -0.44% 640K
|
Health Technology
|
| O: -3.38%
H: 4.35%
C: -3.22%
therapeutics
Iovance Biotherapeutics Appoints Wendy L. Dixon, Ph.D., to Board of Directors
Published: 2022-06-13 (Crawled : 22:00) - biospace.com/
VYGR | News | $7.57 -1.05% -1.06% 310K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -7.41%
IOVA 4 | $11.71 -1.27% -1.45% 2.9M
|
Health Technology
|
| O: -3.73%
H: 1.25%
C: -3.88%
INCY | $51.74 0.17% 0.14% 1.6M
|
Health Technology
|
| O: -3.69%
H: 0.0%
C: 0.0%
BDTX | $5.06 1.0% 0.79% 360K
|
Health Technology
|
| O: -2.8%
H: 3.85%
C: 2.4%
ARVN | $32.54 -4.29% -4.58% 360K
|
Health Technology
|
| O: -3.59%
H: 0.62%
C: -4.45%
ALKS | $24.65 1.61% 1.62% 1.7M
|
Health Technology
|
| O: -2.33%
H: 2.01%
C: 1.94%
FDA Advisory Committee Unanimously Supports beti-cel Gene Therapy for People with beta-thalassemia Who Require Regular Red Blood Cell Transfusions
Published: 2022-06-10 (Crawled : 22:00) - biospace.com/
BLUE | $0.9229 -4.91% -4.66% 7.9M
|
Health Technology
| Email alert
Add to watchlist
fda blood therapy
bluebird bio stock trading halted today June 9th and tomorrow June 10th
Published: 2022-06-09 (Crawled : 12:00) - biospace.com/
BLUE | $0.9229 -4.91% -4.66% 7.9M
|
Health Technology
| Email alert
Add to watchlist
today
bluebird bio Announces Posting of Briefing Documents for Upcoming FDA Advisory Committee Meeting
Published: 2022-06-07 (Crawled : 13:20) - biospace.com/
BLUE | $0.9229 -4.91% -4.66% 7.9M
|
Health Technology
|
| O: -1.01%
H: 22.68%
C: 22.37%
fda
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4253 179.25% 64.77% 210M
|
Consumer Services
BOF | $2.08 77.78% 41.21% 110M
|
ILAG | $0.54 12.27% 40.62% 3.7M
|
LICN | $0.999 78.39% 40.49% 15M
|
AMST | $3.4 70.0% 39.58% 70M
|
Technology Services
MTC | $3.6 60.71% 38.04% 9.1M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.458 14.5% 30.92% 91K
|
Health Services
MULN | News | $3.77 38.1% 27.78% 13M
|
Information
RILY | $29.75 36.97% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.